You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Humanized Monoclonal Antibodies to Treat Acinetobacter Infections

    SBC: BIOLOGICAL ANTI-INFECTIVE MEDICINES, LLC            Topic: NIAID

    DESCRIPTION (provided by applicant): In the last decade, Acinetobacter baumannii has emerged as one of the most highly antibiotic-resistant pathogens in the United States (US) and throughout the world. These infections are increasingly prevalent and highlylethal, killing 50-60% of those infected. Worse, strains of A. baumannii that no known antibiotic will kill have now emerged, and will continue ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  2. Immunotherapeutics to prevent HCV reinfection

    SBC: Integrated Biotherapeutics, Inc.            Topic: NIAID

    DESCRIPTION (provided by applicant): Up to 170 million people worldwide are chronically infected with HCV Hepatitis C virus (HCV) putting the infected individuals at significant risk for cirrhosis, liver failure and liver cancer. End- stage liver diseasecaused by HCV is the leading indication of liver transplantation (LT) in the United States. However, reinfection with HCV occurs universally and ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  3. Preparation and Characterization of 2nd Generation HIV-1 Maturation Inhibitor Dru

    SBC: DFH Pharma, Inc            Topic: NIAID

    DESCRIPTION (provided by applicant): Despite advances in the development of HIV drugs there remains a need for new therapies. Toxicities associated with long term use of many of the approved HIV drugs coupled with the development of resistance drives the need for new and novel antivirals. Maturation inhibitors (MIs) represent one such class of HIV therapies. HIV maturation inhibitors block virus r ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  4. Elucidation of Antisickling Molecules in a Botanical with Antisickling Activity

    SBC: INVENUX, LLC            Topic: NCCAM

    DESCRIPTION: New therapeutic agents are urgently needed for the treatment of sickle cell disease (SCD), the world's most common genetic disease. Our long-term goal is to develop a drug for use in children that prevents the inexorable progression of SCD. SCD affects approximately 100,000 people in the United States and millions worldwide. It kills more children in Africa than HIV, but while HI ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  5. Tumor-toxic CD47 mAb therapy for leukemia: a proof of concept study

    SBC: VASCULOX, INC.            Topic: NCI

    DESCRIPTION (provided by applicant): CD47 has emerged as a novel therapeutic target in hematologic cancers. Leukemias expressing the highest levels of CD47 have the worst prognosis. Increased CD47 expression is thought to protect cancer cells from phagocytic clearance by sending a don't eat me signal to macrophages via SIRPa, an inhibitory receptor that prevents phagocytosis of CD47-bearing ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  6. The anti-tumorigenic and anti-metastatic potential of Eya phosphatase inhibitors

    SBC: SIXONE SOLUTIONS, LLC            Topic: NCI

    DESCRIPTION (provided by applicant): Breast cancer is expected to cause 39,510 deaths of American women in 2012 and 450,000 deaths globally. Once breast cancer has spread, it is essentially incurable. A critical barrier to treating advanced breast cancer is the lack of cancer-specific drugs that are effective in a large percentage of cancer patients and have low toxicity. Sixone Solutions, LLC pro ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  7. Mobile App Targeting Meth Use, HIV Sex Risks and ART Adherence for Gay/Bisexual Men

    SBC: COG ANALYTICS, LLC            Topic: NIDA

    DESCRIPTION (provided by applicant): Methamphetamine use among gay and bisexually identified men (GBM) and other men who have sex with men (MSM) is strongly associated with HIV infection due to the concomitant high-risk sexual behaviors that often occur while using the drug. As a result, HIV prevalence is significantly higher among MSM that report frequent use of methamphetamine and highest among ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  8. Communication in Infants and Social Screener: The CISS

    SBC: PAUL H BROOKES PUBLISHING CO., INC.            Topic: NIDCD

    DESCRIPTION (provided by applicant): Effective early intervention depends on reliable screening of risk for communication impairments as soon as possible. Established infant communication risk factors include poor attention, gestures, social connectedness,exploratory play, and speech. Although these risk factors can be detected by 12-18 mos. and reliably predict later language and social disorders ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  9. Non-invasive method to evaluate the quality of human oocytes and embryos

    SBC: Renova Life Inc.            Topic: NICHD

    DESCRIPTION (provided by applicant): Project Summary We propose to develop a non-invasive method to predict mammalian oocyte quality by analyzing the surrounding cumulus cells' gene expression patterns (cGEP). The result of the cGEP assay---a cGEP score---can be used to predict embryo quality and ultimately the embryo transfer (ET) results. This technology, if success, will for the first time ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  10. Remote focusing through spatial light modulation for multifocal multiphoton micro

    SBC: BOULDER NONLINEAR SYSTEMS, INC.            Topic: NIMH

    DESCRIPTION (provided by applicant): Nonlinear optical microscopy techniques (such as two-photon florescence) are being used to acquire volumetric (i.e. three dimensional) images that probe several hundred microns into scattering tissue. These techniques are being combined with fast acquisition schemes to allow imaging of live, moving specimens at high NA. This combination allows for high-resoluti ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government